Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Tailoring treatment of rectal adenocarcinoma: immunohistochemistry for predictive biomarkers.

Kapur P.

Anticancer Drugs. 2011 Apr;22(4):362-70. doi: 10.1097/CAD.0b013e3283433764. Review.

PMID:
21233707
2.

p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.

Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, Clarke S, Chapuis P, Solomon MJ.

Dis Colon Rectum. 2003 Feb;46(2):192-202.

PMID:
12576893
3.
4.

[Correlation of VEGF and Ki67 expression with sensitivity to neoadjuvant chemoradiation in rectal adenocarcinoma].

Jiang SM, Wang RB, Yu JM, Zhu KL, Mu DB, Xu ZF.

Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):602-5. Chinese.

PMID:
19102938
5.

Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, Luppi G, Conte PF.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1455-61. Epub 2007 Apr 18.

PMID:
17445998
6.

Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.

Toiyama Y, Inoue Y, Saigusa S, Okugawa Y, Yokoe T, Tanaka K, Miki C, Kusunoki M.

Clin Oncol (R Coll Radiol). 2010 May;22(4):272-80. doi: 10.1016/j.clon.2010.01.001. Epub 2010 Feb 1.

PMID:
20117921
7.

p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma.

Luna-Perez P, Arriola EL, Cuadra Y, Alvarado I, Quintero A.

Ann Surg Oncol. 1998 Apr-May;5(3):203-8.

PMID:
9607618
8.

Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.

Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH.

Cancer. 2007 May 1;109(9):1750-5.

9.

Overexpression of nuclear β-catenin in rectal adenocarcinoma is associated with radioresistance.

Wang L, Zhang XM, Li Z, Liu XJ, Chai J, Zhang GY, Cheng YF.

World J Gastroenterol. 2013 Oct 28;19(40):6876-82. doi: 10.3748/wjg.v19.i40.6876.

10.

Preoperative radiotherapy modulates ezrin expression and its value as a predictive marker in patients with rectal cancer.

Korkeila EA, Syrjänen K, Bendardaf R, Laulajainen M, Carpén O, Pyrhönen S, Sundström J.

Hum Pathol. 2011 Mar;42(3):384-92. doi: 10.1016/j.humpath.2010.08.004. Epub 2010 Dec 28.

PMID:
21190723
11.

Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer.

Tweedle EM, Khattak I, Ang CW, Nedjadi T, Jenkins R, Park BK, Kalirai H, Dodson A, Azadeh B, Terlizzo M, Grabsch H, Mueller W, Myint S, Clark P, Wong H, Greenhalf W, Neoptolemos JP, Rooney PS, Costello E.

Gut. 2010 Nov;59(11):1501-10. doi: 10.1136/gut.2009.196626.

PMID:
20947885
12.

L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer.

Ebara T, Kaira K, Saito J, Shioya M, Asao T, Takahashi T, Sakurai H, Kanai Y, Kuwano H, Nakano T.

Anticancer Res. 2010 Oct;30(10):4223-7.

PMID:
21036745
13.

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C.

J Clin Oncol. 2006 Sep 1;24(25):4062-8.

PMID:
16943523
14.

Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status.

Read TE, Andujar JE, Caushaj PF, Johnston DR, Dietz DW, Myerson RJ, Fleshman JW, Birnbaum EH, Mutch MG, Kodner IJ.

Dis Colon Rectum. 2004 Jun;47(6):825-31. Epub 2004 Apr 19.

PMID:
15108025
15.

Distal margins in radical resections for rectal cancer after chemoradiation therapy: how short is long enough?

Pricolo VE, Abodeely A, Resnick M.

Dig Surg. 2010 Aug;27(3):185-9. doi: 10.1159/000274464. Epub 2010 Jun 22.

PMID:
20571264
16.

P27 does not predict histopathological response to radiochemotherapy in rectal cancer.

Günther K, Dimmler A, Rödel F, Reulbach U, Merkel S, Bittorf BR, Matzel KE, Papadopoulos T, Hohenberger W, Sauer R, Rödel C.

J Surg Res. 2003 Aug;113(2):179-88.

PMID:
12957127
17.

The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.

Lindebjerg J, Spindler KL, Ploen J, Jakobsen A.

Colorectal Dis. 2009 Mar;11(3):264-9. doi: 10.1111/j.1463-1318.2008.01599.x. Epub 2008 Jun 20.

PMID:
18573119
18.

Molecular responses of rectal cancer to preoperative chemoradiation.

Debucquoy A, Goethals L, Geboes K, Roels S, Mc Bride WH, Haustermans K.

Radiother Oncol. 2006 Aug;80(2):172-7. Epub 2006 Aug 14.

PMID:
16905208
19.

Increased endocrine cells in treated rectal adenocarcinomas: a possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy.

Shia J, Tickoo SK, Guillem JG, Qin J, Nissan A, Hoos A, Stojadinovic A, Ruo L, Wong WD, Paty PB, Weiser MR, Minsky BD, Klimstra DS.

Am J Surg Pathol. 2002 Jul;26(7):863-72. Erratum in: Am J Surg Pathol 2002 Sep;26(9):1241.

PMID:
12131153
20.

T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival.

Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, Taylor CW, Aguilar PS, Khanduja KS.

Dis Colon Rectum. 2002 Jul;45(7):895-903.

PMID:
12130878

Supplemental Content

Support Center